Although this mechanism needs to be further confirmed in other animal models (e.g., a stress-induced model of chronic visceral pain), our findings provide a probable potential therapeutic strategy by targeting GATA1 and the p2x7r locus binding in the clinical management of patients with gastrointestinal diseases such as IBS. This evidence concerns the gene GATA1 and gastrointestinal disease.